Table 1

AR positivity in different tumors

Tumor

Total (M+F)

AR Positive Nuclear or Nuclear-Cytoplasmic immunoreactivity %(n)

Cytoplasmic immunoreactivity

IDC

29 (All F)

48% (14/29)

55%(16/29)

ILC

5 (All F)

100% (5/5)

100% (5/5)

Ovary

10*

20% (2/10)

90% (9/10)

Endometrium

7

0% (0/7)

43%(3/7)

Cervix

6

0% (0/7)

17%(1/6)

Lung

23 (6 + 17)**

0% (0/23)

74%(17/23)

Colon

9 (2+7)***

0% (0/9)

78%(7/9)

Stomach

6 (4+2)****

0% (0/6)

50%(3/6)

Pancreas

7 (2+5)

0% (0/7)

43%(3/7)

Hepatobiliary

11 (5+6)

0% (0/11)

18%(2/11)

*Included 5 papillary serous adenocarcinomas, 3 endometrioid carcinomas, 1 mixed papillary mucinous and serous adenocarcinoma, and 1 mixed endometrioid and papillary serous adenocarcinoma.

** Included 13 poorly differentiated adenocarcinomas of lung and 10 bronchoalveolar carcinomas.

*** Initially 10 cases of colon adenocarcinoma were selected but one was excluded after concluding it to be metastatic prostrate adenocarcinoma to colon.

**** Initially 7 cases of gastric carcinoma were selected but one was later excluded following conclusion of it being metastatic mammary carcinoma to stomach.

Shidham et al. Diagnostic Pathology 2006 1:34   doi:10.1186/1746-1596-1-34